forbidden flower Florida health rules on medical marijuana bolsters the heavily regulated status quoBy Erin Clark of Watchdog.org Please enter your comment! Red tape, red tape…..the voters get irked when what they vote for and get approved on the ballot doesn’t go forth because of red tape. Terminally ill people are suffering while the debate goes on and on over medical marijuana. As far as ” Old Arthur” in your joints and its stiffness…..old timer, Ansel, an old stove-up fella from around these parts, now long long gone, used to spray W-D 40 on his knees caps, and drank his malt liquor faithfully…..he swore by it, and that he felt no pain from “Old Arthur”………LOL! When Florida voters passed Amendment 2 with a 71 percent approval rate last November, they thought they were getting a widened medical marijuana marketplace that a large new swath of patients could access with less regulatory interference.But the first set of new regulations proposed Tuesday by the Florida Department of Health would reinforce the preexisting regulatory structure, which allowed only a handful of farms to produce low-THC product for the Florida marketplace.“I’d say the expected result was what just happened,” California attorney Matt Harrison told Watchdog.org. Harrison helped draft California’s Prop 64, which decriminalized adult use of cannabis in the state.“In the political reality and how administrative agencies work, it’s very typical that they would do something like that because it’s the whole hammer and nail syndrome, where they would be given this authorization to regulate this new area and they would imagine that it gives them some sort of mandate to do it the exact same way they did it previously.”Medical marijuana has been a hot topic in Florida for several years. In 2014, a ballot measure very similar to 2016’s successful Amendment 2 failed, but a decriminalization bill passed the legislature: the Compassionate Medical Cannabis Act of 2014. The bill decriminalized low-THC cannabis use for a limited number of patients under strict guidelines. It also allowed for there to be only five carefully regulated medical marijuana dispensaries in the state.The 2014 bill also established a system in which the marketplace was vertically integrated. Under this structure, someone has to not only grow the product but process it in-house and sell it.“I don’t think the amendment calls for or contemplates that it has to be a vertically integrated structure, which is currently being proposed and which we currently operate under,” State Sen. Jeff Brandes, R-St. Petersburg, told Watchdog. He identified vertical integration as one of the problems with the existing Florida medical marijuana market.“If you’re good at growing, cultivating marijuana, you should be able to grow the product, but that doesn’t mean necessarily that you need to be good at retail. Conversely, if you’re good at retail, you don’t have to be necessarily good at growing.”He argued the current proposal smacks of industry insiders trying to limit market access. “They want to control certain regions, they want to be able to limit competition, limit who can actually grow, produce and ultimately retail, sell medical marijuana in the marketplace. That is, by definition, a cartel.” A system that artificially contracts production could mean problems for the expanded pool of patients for which Amendment 2 opened the floodgates.“We are talking about a situation where there is going to be significant demand in the marketplace, and there is very likely not going to be sufficient supply,” Paul Armentaro, deputy director of marijuana law reform group NORML, told Watchdog.Harrison concurred. “If you’re looking to provide a product to a larger subset of the population [vertical integration] is something that could cause a lot of bottlenecks in supply and is not something that would be considered efficient.”However, Harrison believes the increased demand for product might help evolve the regulations.A SELECT FEW: The medical marijuana marketplace in Florida is closed to all but a handful of dispensaries.“Ask the experts, anybody who’s familiar with the types of conditions the prior regime qualified for and what Amendment 2 is clearly encompassing or intending to encompass. It would create a need to supply the market in a new and different way.”Of course, Florida lawmakers don’t need to reinvent the wheel here, with two decades of various forms of legal marijuana precedent to draw from in other states. Armentaro mentioned Colorado and Oregon as examples of more sophisticated marketplaces that Florida legislators could draw from, although the regulatory process has impeded the marketplace in those states as well.Armentaro added that another provision of the proposed regulations goes against the promise of increased access of A2: the proposed set of qualifying medical conditions. He argued, “the proposed rules take discretion away from the physician and instead leave it up to regulators to determine 10 arbitrary conditions.”“What is not included in these conditions is chronic pain, the single condition for which the most patients currently use medical marijuana and the condition for which there is the largest volume of gold-standard clinical evidence showing that marijuana is safe and effective for,” Armentaro said, citing a recently released study by the National Academies.Who figures?In addition to state regulatory agencies, cities and municipalities are throwing moratoriums into the gears of Amendment 2, justifying the practice by citing the regulatory dispute over how the amendment will be enacted. According to Harrison, this is no surprise.“It’s what happened in Colorado, too. It’s a really convenient excuse when there’s regulatory uncertainty or policy uncertainty and so the local governments kind of seize on that and say well we don’t want it unless someone else figures it out. And so the question is who does the figuring out.”Another complicating issue involves Florida’s snowbirds and reciprocity between states. Jodi James, executive director of the Florida Cannabis Action Network, told Watchdog, “I have thousands of people every year who come down from Michigan every year, Michigan, Ohio Illinois, Minnesota… they are all medically legal states. These people who come down for four months a year cannot use their medication legally in the state of Florida. There is no reciprocity for them.”Legislators weigh inState Sen. Bradley, R-Fleming Island, introduced a bill this month, proposed several days after the DOH guidelines were released, addressing some of the issues with the Department of Health rules.The state currently licenses seven dispensing organizations. Bradley’s bill would increase that cap to 20, once there are 500,000 registered medical marijuana patients. However, it does not disrupt the vertically integrated dispensary structure.The bill also explicitly expands access to patients with “chronic non-malignant pain,” and returns some of the discretionary power the DOH had assumed back to physicians while lowering the standards for becoming licensed to prescribe medical marijuana.Another view for what Florida’s medical marijuana regulatory regime could look like will come from Brandes, who told Watchdog that a counter-bill with a more free-market slant will be introduced shortly.“We need a structure that is something with high standards, high insurance requirements, high bonding requirements, that are letting legitimate players pick what portions of the market they actually want to participate in.”He added the need to set standards that were “reasonable and rational” for what type of training physicians should undergo before being allowed to prescribe, which the Bradley bill likewise addresses.The need for physician training was echoed by Armentaro, who added that many physicians hadn’t been previously exposed to medical marijuana education.“Of course, more hurdles put in place could potentially limit the pool of doctors willing to participate in this system. For better or for worse, physicians are the gatekeepers.”At the moment, only 1 percent of Florida doctors are licensed to prescribe medical marijuana.Brandes said the upcoming regulatory dispute would boil down to a battle of ideas over what type of say government regulators should have over the marketplace.“My hope is that the house, the governor and the FL senate will be consistent in its free-market philosophy on this topic,” Brandes said. “That they will make sure that whatever they do, that they’re allowing all Floridians to participate, not limiting it to a handful of folks who have the money to stop them at the legislative level.” Mama Mia UF/IFAS in Apopka will temporarily house District staff; saves almost $400,000 LEAVE A REPLY Cancel reply Gov. DeSantis says new moment-of-silence law in public schools protects religious freedom You have entered an incorrect email address! Please enter your email address here TAGSMedical Marijuana Previous articlePrescribed burns benefit natureNext articleCity hires independent engineering consultant for wastewater facility Denise Connell RELATED ARTICLESMORE FROM AUTHOR January 24, 2017 at 11:53 am Florida gas prices jump 12 cents; most expensive since 2014 1 COMMENT Reply Erin Clark is a Florida reporter for Watchdog.org. A graduate of the University of Richmond, Clark competed on the professional tennis circuit for several years before returning to writing. Her work has been republished on Townhall and other news sources. She can be reached at [email protected] Please enter your name here Share on Facebook Tweet on Twitter Save my name, email, and website in this browser for the next time I comment.
Facebook Twitter By Andy Eubank – Jun 15, 2016 SHARE NutrientStar part of 4R SummitWednesday begins a 2-day gathering in Indianapolis of The Fertilizer Institute’s annual 4R Summit featuring educational sessions on how the 4Rs, Right Source, Right Rate, Right Time, Right Place, help with day-to-day crop production practices. Growers, retailers, government partners, and researchers will discuss the 4R Nutrient Stewardship efforts and impacts.An update on NutrientStar is scheduled for 9:00 AM Thursday. Environmental Defense Fund Agricultural Sustainability Project Manager Karen Chapman says it is a review program to assess the performance of the many products and decision support tools available to farmers.“We wanted to be able to provide information about those tools and products to farmers and their advisors. We started NutrientStar as an independent and objective assessment program to look at those tools and products. It relies on a science panel of experts who actually crafted the criteria and the protocol that we use for assessment, primarily around fertilizer management and nutrient use efficiency.”NutrientStar needs data to be valuable and effective, and Chapman said right now there is surprisingly little data available.“We are really reaching out to companies and establishing this mutually beneficial relationship that will only benefit companies, and they’ll understand the research standards that we’re promulgating and that they are not overwhelmingly difficult to follow. Working with these companies, sharing the protocol, talking to them about the goals of NutrientStar, I think over time we will definitely have more data, better data, and the ability to really shine the light on the performance of these tools and products as we collect that data.”Learn more at the NutrientStar website, and hear more from Chapman here:Karen Chapman-NutrientStarAlso learn more about the 4R Summit being held at the Hilton Indianapolis Hotel and Suites:From The Fertilizer Institute: FARMER AND RETAILER TO LEAD SESSION DURING THE FERTILIZER INSTITUTE’S 4R SUMMITWASHINGTON, D.C., – Award-winning retailer Mike Wilson from Wabash Valley FS, Grayville, Ill., and farmer Tom Connors, Shipman, Ill., will headline a session on implementing 4Rs in the field at The Fertilizer Institute’s annual 4R Summit. The Summit provides opportunities for those interested in nutrient management and stewardship to learn more about the 4R Nutrient Stewardship program and hear from 4R stakeholders, including growers, retailers, government partners, researchers, and others, about 4R Nutrient Stewardship efforts and impacts.The event starts at 8:00 a.m., Wednesday, June 15th at the Hilton Indianapolis Hotel and Suites, 120 West Market Street, in Indianapolis, Ind. It is open to farmers, agribusiness professionals, and stakeholders nationwide. Meeting registration is available at the 4R website, www.nutrientstewardship.com or by calling 800-315-1906. An agenda is available online.Wilson and Connors were named 4R Advocates by TFI in 2013 and 2016 respectively. 4R Advocates are recognized annually for their exceptional nutrient stewardship practices that include the 4R approach. It helps growers meet production and environmental goals by choosing the right nutrient source to apply at the right rate in the right place at the right time.“I’ve used the 4Rs since the 1990s,” Connors said. “I look for ways to be proactive, to behave responsibly for the environment and social good and provide a sustainable operation that my family can farm for generations to come.”The two-day event features educational sessions to learn how the 4Rs help with day-to-day crop production practices. Attendees can also take in how the science of 4Rs fits in soil health improvement plans, nutrient management, water quality management and conservation plans.Presenters include: Chase Koch, Koch Agronomic Services; Marty Adkins, Steve Davis, Mark Smith, and Norm Widman, National Resources Conservation Service; Matt Helmers, Iowa State University; Ton Vyn, Purdue University; Nathan Nelson, Kansas State University; Wayne Honeycutt, Soil Health Institute and Scott Murrell, International Plant Nutrition Institute.“The 4R Summit is an event where growers and agribusiness personnel can share success stories and see how proven environmental stewardship enhances food production practices,” said Chris Jahn, TFI President. “Growers, retailers and others who attend will be excited about the innovative ideas shared.” SHARE NutrientStar Among Updates for Indy 4R Summit Home Indiana Agriculture News NutrientStar Among Updates for Indy 4R Summit Facebook Twitter Previous articleLawsuit Over Pork Slogan Continues This SummerNext articleMorning Outlook Andy Eubank
Respect judicial independence in cases of two leading journalists in Serbia and Montenegro, RSF says April 12, 2005 – Updated on January 20, 2016 Six years of impunity for Slavko Curuvija’s murderers Europe – Central Asia June 4, 2021 Find out more Organisation Receive email alerts Help by sharing this information Europe – Central Asia News News On the sixth anniversary of the murder of Serb journalist Slavko Curuvija on 11 April 1999, Reporters Without Borders today deplored the failure to identify his killers and bring them to justice and it reiterated its call to the Serbian authorities to establish all the facts related to the case.”No relevant information is yet available about Slavko Curuvija’s killers,” the press freedom organization said in a letter to the interior minister. “We are dismayed by the lack of results and the failure of the Serbian authorities to carry out an investigation capable of finding out the truth about this case.”The letter continued: “Despite the repeated promises to solve this case, it is clear that the investigations are at a standstill. Curuvija’s family and his colleagues in Serbia and the rest of the world have a right to know the truth. We once again call on the authorities to do everything possible to clarify all the precise circumstances of this tragedy.”Justice minister Zoran Stojkovic yesterday said there was no real evidence available on the circumstances of Curuvija’s death, despite the creation of a special investigative unit within the police just to work on this case.According to sources within the interior ministry, police inspector general Vladimir Bozovic requested documents about the Curuvija case in September 2004 and obtained nothing from the police then in charge of the investigation.On 9 December 2003, a few days before legislative elections, the office of the special prosecutor and the organised crime bureau said an eye-witness had formally identified two persons suspected of the murder but their identity could not be revealed. Since then, the police have given no further information about the outcome of this identification.The daily newspaper Politika has alleged that three policemen from the Republic of Srpska (a Bosnian Serb entity) are implicated in Curuvija’s death, while Luka Pejovic, a Montenegrin who was identified as Curuvija’s killer by a witness, was innocent. Pejovic was gunned down outside his Belgrade home on 5 December 2000.According to Natasa Kandic of the Humanitarian Law Centre (HLC), a Serbian human rights NGO that was the first to discover that Curuvija was under close police surveillance at the time of his murder, those implicated in his death still have a close relationship with the Serbian national security agencies, and this explains why the investigation has not progressed.Curuvija, who edited the newspapers Dnevni Telegraf and Evropljanin, was shot dead by two masked men as he arrived in front of his Belgrade home with his wife on 11 April 1999, at the time of the NATO military offensive. He had been constantly harassed for his articles criticising the regime of President Slobodan Milosevic. Some state-owned newspaper called him a “traitor.” June 8, 2021 Find out more to go further RSF calls for a fully transparent investigation after mine kills two journalists in Azerbaijan Serbian journalist Slavko Curuvija was gunned down outside his home in Belgrade by two masked men on 11 April 1999. On the six anniversary of his death, there is still no information available about the identity of his killers. Reporters Without Borders reiterates its call to the Serbian authorities to shed light on all aspects of the case. “We’ll hold Ilham Aliyev personally responsible if anything happens to this blogger in France” RSF says RSF_en News June 7, 2021 Find out more News Follow the news on Europe – Central Asia
3 recommended0 commentsShareShareTweetSharePin it Coconut MangoFreedom extends to more than just our civil liberties, freedom of choice is a dessert right that you can exercise freely at U Pick Cafe. Have full liberty of your dessert selections and try something new. More Cool Stuff U Pick Cafe also offers two more traditional desserts, Rosewater Pistachio and Baklava. faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Virtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes Top of the News Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. “The Rosewater Pistachio, it’s a gelato. It’s a traditional Persian taste. It’s creamy; it’s pistachio gelato and its rosewater and saffron in it. It’s very different. It has a very unique taste to it,” said Arin Navasartian, One of the founders of U Pick Cafe. “So it’s very delicious and has a strong rosewater taste it’s a special mixture of flavors.” They also serve Baklava, a traditional middle-eastern dessert made with nuts and honey, baked by a local Armenian lady. Baklava and Chocolate Raspberry Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDS Subscribe Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadena U Pick Cafe offers Chocolate Raspberry- Chocolate Gelato with a heart of raspberry sorbet covered with cocoa powder and Coconut Mango -Coconut with a heart of mango sorbet covered with shredded coconut. Your email address will not be published. Required fields are marked * Make a comment Call (626) 808-9802 for Pasadena, (323)344-7443 for Highland Park or visit www.upickcafe.com for more details. They also have refreshing vegan options like Mango sorbet served in natural mango shell andCoconut Sorbet served in natural coconut shell. First Heatwave Expected Next Week Name (required) Mail (required) (not be published) Website Herbeauty9 Hollywood Divas Who Fell In Love With WomenHerbeautyHerbeautyHerbeautyGet Rid Of Unwanted Body Fat By Eating The Right FoodsHerbeautyHerbeautyHerbeauty14 Effortless Looks That Make Men StareHerbeautyHerbeautyHerbeauty12 Female Fashion Trends That Guys Can’t StandHerbeautyHerbeautyHerbeautyRed Meat Is Dangerous And Here Is The ProofHerbeautyHerbeautyHerbeauty7 Reasons Why The Lost Kilos Are Regained AgainHerbeautyHerbeauty Community News Finally, another favorite is the New York Cheesecake with a hint of vanilla. “I’m not a big fan of cheesecakes over all but this one, It’s very creamy and delicious,” he said. The cheesecake comes with raspberry sauce drizzled on top. Have your pick at U Pick Cafe. They are located at 720 North Lake Avenue, Pasadena and 4682 York Blvd in Highland Park. Business News Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday Community News Pasadena Eats, The Dining Blog Sweet Dessert Choices at U Pick Cafe From STAFF REPORTS Published on Thursday, December 17, 2015 | 1:14 pm
NewsBusiness#WATCH Johnson & Johnson Limerick facility expansion to create approximately 100 jobs with €100M investmentBy Staff Reporter – April 8, 2019 1474 Medical photo created by freepik – www.freepik.comMinister of State for Trade, Employment and Business, Pat Breen TD today announced that Johnson & Johnson Vision Care (Ireland) will be adding approximately 100 new roles as part of about a €100M expansion of its manufacturing operations at its site in the National Technology Park, Plassey, Limerick.The project is supported by the Irish Government through IDA Ireland.Sign up for the weekly Limerick Post newsletter Sign Up Approximately 200 additional workers are expected to be employed in the construction phase of the expansion to the company’s Vision Care facility.Speaking at today’s announcement, Minister of State for Trade, Employment & Business Pat Breen TD said: “I very much welcome Johnson and Johnson Vision Care’s expansion of its operations in Limerick and of course the approximately 100 jobs that will be created. It is a huge vote of confidence in the Mid-West region. The expansion, supported by the Government through the IDA, reflects the commitment of the Government and its agencies to pursue balanced and sustainable regional development.”John Lynch, Plant Leader, Johnson & Johnson Vision Care (Ireland) said: “Our aspiration at Johnson & Johnson Vision is to bring improved eyesight to people around the world and the most important way we accomplish that is through the research, development and manufacturing of new medical device technologies. We believe that the new manufacturing roles being introduced in Limerick in 2019 will be foundational in helping us bring new, innovative contact lens products to our patients and customers around the world at an industry-leading pace.”IDA Ireland CEO Martin Shanahan said: “This is a significant announcement. Already the world’s largest contact lenses manufacturing plant, this expansion by Johnson & Johnson Vision Care of the Limerick facility represents not just a substantial financial investment but a considerable commitment to its Limerick operations. The approximately 100 jobs being added, along with those being created in the construction phase, will greatly benefit the economy of the Mid West region. Having a company of this stature continue to expand its operations enhances Ireland’s global reputation as a Medical Technologies centre of excellence and demonstrates how global companies can successfully operate in regional locations. I wish John and his team continued success.” Advertisement Housing 37 Compulsory Purchase Orders issued as council takes action on derelict sites Print Ann & Steve Talk Stuff | Episode 29 | Levelling Up Facebook WhatsApp Limerick on Covid watch list Linkedin Limerick businesses urged to accept Irish Business Design Challenge Email Previous articleCity and Soul: ADAPT gives shelter in Limerick CityNext articleGardaí recover 3,000-year-old Bronze Age axe after illegal unearthing with metal detector in Limerick Staff Reporterhttp://www.limerickpost.ie TAGSbusinessjohnson & johnson VisionLimerick City and CountyNews Twitter Exercise With Oxygen Training at Ultimate Health Clinic RELATED ARTICLESMORE FROM AUTHOR TechPost | Episode 9 | Pay with Google, WAZE – the new Google Maps? and Speak don’t Type!
24.15% $17,418,000 PrincipalAmountTendered as of theEarly TenderDeadline Offer Yield (1) 4 Bristol Myers Squibb 110122AP3 NEW YORK–(BUSINESS WIRE)–Feb 19, 2021– Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb”), with its wholly-owned subsidiary Celgene Corporation (“Celgene”) (collectively, the “Offerors”), announced the accepted amounts and pricing terms of their previously announced 20 separate offers to purchase for cash notes issued by the Offerors listed in the tables below for up to an aggregate purchase price of $4.0 billion. The table below indicates, among other things, the aggregate principal amount of Notes tendered as of 5:00 p.m. (New York City time) on February 18, 2021 (the “Early Tender Deadline”) and accepted in each Offer, the Offer Yield (each as defined below), the proration factor, if any, and the total consideration for each $1,000 principal amount of each series of Notes validly tendered at or prior to the Early Tender Deadline and accepted for purchase (the “Total Consideration”), as calculated at 11:00 a.m. (New York City time) today, February 19, 2021 in accordance with the terms of the Offer to Purchase dated February 4, 2021 (the “Offer to Purchase”): 2023 Pool Offers to purchase for cash up to $950,000,000 aggregate purchase price for the securities listed in the priority order below. $1,158.68 Title of Security Local NewsBusiness 6 PrincipalAmountOutstanding 4.000% Notes due 2023 * Denotes a series of Notes for which the Total Consideration, the Tender Consideration (as defined in the Offer to Purchase), and the Offer Yield were determined taking into account the par call date, instead of the maturity date, of the Notes of such series in accordance with standard market practice. The outstanding debt securities listed in (i) the first table above labeled “2023 Pool” are referred to collectively as the “2023 Pool Notes,” (ii) the second table above labeled “2024 Pool” are referred to collectively as the “2024 Pool Notes,” (iii) the third table above labeled “2025 Pool” are referred to collectively as the “2025 Pool Notes,” and (iv) the fourth table above labeled “High Coupon Pool” are referred to collectively as the “High Coupon Pool Notes.” The High Coupon Pool Notes, the 2023 Pool Notes, the 2024 Pool Notes and the 2025 Pool Notes are referred to collectively as the “Notes,” and each series of Notes is referred to as a “series.” We refer to each offer to purchase a series of Notes for cash as an “Offer,” the offers to purchase the 2023 Pool Notes collectively as the “2023 Pool Offers,” the offers to purchase the 2024 Pool Notes collectively as the “2024 Pool Offers,” the offers to purchase the 2025 Pool Notes collectively as the “2025 Pool Offers,” the offers to purchase the High Coupon Pool Notes collectively as the “High Coupon Pool Offers,” and all the offers to purchase Notes are referred to collectively as the “Offers.” The Offerors’ obligations to accept Notes tendered in the Offers are subject to the terms and conditions described in the Offer to Purchase, which sets forth a detailed description of the Offers, including (i) the Acceptance Priority Procedures (as defined in the Offer to Purchase), (ii) a $950 million maximum aggregate purchase price of the 2023 Pool Notes validly tendered in the 2023 Pool Offers, excluding the applicable Accrued Coupon Payments (as defined below) (the “2023 Pool Maximum”), (iii) a $1.5 billion maximum aggregate purchase price of the 2024 Pool Notes validly tendered in the 2024 Pool Offers, excluding the applicable Accrued Coupon Payments (the “2024 Pool Maximum”), (iv) a $650 million maximum aggregate purchase price of the 2025 Pool Notes validly tendered in the 2025 Pool Offers, excluding the applicable Accrued Coupon Payments (the “2025 Pool Maximum”), and (v) a $900 million maximum aggregate purchase price of the High Coupon Pool Notes validly tendered in the High Coupon Pool Offers, excluding the applicable Accrued Coupon Payments (the “High Coupon Pool Maximum”). The withdrawal rights for the Offers expired at 5:00 p.m. (New York City time) on February 18, 2021. As previously announced, all conditions of the Offers were deemed satisfied or waived by the Offerors by the Early Tender Deadline. As previously announced, the Offerors have elected to exercise their Early Settlement Right (as defined in the Offer to Purchase). The Early Settlement Date (as defined in the Offer to Purchase) will occur on February 23, 2021. The Offers will each expire at 11:59 p.m. (New York City time) on March 4, 2021, unless extended or earlier terminated by the Offerors (such date and time with respect to an Offer, as the same may be extended with respect to such Offer, the “Expiration Date”). Since the aggregate purchase price of the 2024 Pool Notes, 2025 Pool Notes, and High Coupon Pool Notes (excluding the applicable Accrued Coupon Payments) exceeds the 2024 Pool Maximum, 2025 Pool Maximum, or High Coupon Pool Maximum, as applicable, the Offerors will accept such Notes for purchase according to the Acceptance Priority Procedures and proration steps as described in the Offer to Purchase. Holders of Notes (each, a “Holder” and collectively, “Holders”) validly tendered at or prior to the Early Tender Deadline that are accepted for purchase by the Offerors will receive the applicable Total Consideration, in cash. However, because the aggregate purchase price of the 2024 Pool Notes, 2025 Pool Notes, and High Coupon Pool Notes (excluding the applicable Accrued Coupon Payments) exceeds the 2024 Pool Maximum, 2025 Pool Maximum, or High Coupon Pool Maximum, as applicable, there will be no Final Settlement Date (as defined in the Offer to Purchase) and no additional tenders of Notes will be accepted for purchase by the Offerors after the Early Tender Deadline with respect to any 2024 Pool Notes, 2025 Pool Notes, or High Coupon Pool Notes. As described in the Offer to Purchase, the 2024 Pool Notes, 2025 Pool Notes, and High Coupon Pool Notes tendered and not accepted for purchase will be promptly returned to the tendering Holder’s account. Since the aggregate purchase price of the 2023 Pool Notes (excluding the Accrued Coupon Payments) validly tendered at or prior to the Early Tender Deadline and accepted for purchase did not meet or exceed the 2023 Pool Maximum, the Offerors will continue to accept for purchase 2023 Pool Notes up to the 2023 Pool Maximum until the Expiration Date. Holders of the 2023 Pool Notes that are validly tendered after the Early Tender Deadline and prior to the Expiration Date and accepted for purchase subject to the terms and conditions described in the Offer to Purchase will receive the applicable Tender Consideration, which is equal to the applicable Total Consideration minus the Early Tender Premium. The Final Settlement Date of the 2023 Pool Notes that are validly tendered and not validly withdrawn prior to the Expiration Date is expected to be on or about March 8, 2021. The Total Consideration that will be paid on the Early Tender Deadline for each series of notes accepted for purchase does not include a cash payment equal to accrued and unpaid interest (the “Accrued Coupon Payment”) on such Notes to, but not including, the relevant Settlement Date (as defined in the Offer to Purchase). For the avoidance of doubt, interest will cease to accrue on the Settlement Date for all Notes accepted in the Offers. Under no circumstances will any interest be payable to Holders because of any delay on the part of Global Bondholder Services Corporation, as the tender agent and information agent, The Depository Trust Company or any other party in the transmission of funds to Holders. See the Offer to Purchase for additional information. All Notes accepted in the Offers will be cancelled and retired and will no longer remain outstanding obligations of the relevant Offeror. Following the Price Determination Date, the Offerors may elect to redeem all of Bristol Myers Squibb’s 4.000% Notes due 2023 or Celgene’s 4.000% Notes due 2023 that are not tendered and accepted in the Offers in accordance with the terms of the optional redemption provisions in the indentures governing such Notes. The Offerors have retained Deutsche Bank Securities Inc. and Morgan Stanley & Co. LLC as dealer managers for the Offers. Questions regarding terms and conditions of the Offers should be directed to Deutsche Bank Securities Inc. at (866) 627-0391 (toll-free) or (212) 250-2955 (collect) or Morgan Stanley & Co. LLC at (800) 624-1808 (toll-free) or (212) 761-1057 (collect). Global Bondholder Services Corporation is acting as the tender agent and the information agent for the Offers. This announcement is for informational purposes only. This announcement is not an offer to sell or purchase, a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to any of Notes described herein. The Offers are being made solely pursuant to the Offer to Purchase. The Offers are not being made to Holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In any jurisdiction in which the securities laws or blue sky laws require the Offers to be made by a licensed broker or dealer, the Offers will be deemed to be made on behalf of the Offerors by the dealer managers or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction. This communication is not being made by, and has not been approved by, an authorized person for the purposes of Section 21 of the Financial Services and Markets Act 2000, as amended (the “FSMA)”. Accordingly, this communication is not being distributed to, and must not be passed on to, persons within the United Kingdom save in circumstances where section 21(1) of the FSMA does not apply. Accordingly, this communication is only addressed to and directed at (i) persons that are outside the United Kingdom or (ii) persons in the United Kingdom falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”)) or within Article 43 of the Financial Promotion Order, or to other persons to whom it may otherwise lawfully be communicated under the Financial Promotion Order, all such persons together being referred to as “Relevant Persons”. Any investment or investment activity to which this communication relates is available only to and will be engaged in only with Relevant Persons, and any person who is not a Relevant Person should not rely on it. In the European Economic Area, this communication is only directed at qualified investors as defined in Article 2 of Regulation (EU) 2017/1129. Cautionary Statement Regarding Forward-Looking Statements This press release contains certain forward-looking statements regarding, among other things, statements relating to goals, plans and projections regarding Bristol Myers Squibb’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements are likely to relate to, among other things, Bristol Myers Squibb’s ability to execute successfully its strategic plans, including its business development strategy generally and in relation to its ability to realize the projected benefits of the acquisitions of Celgene and MyoKardia, Inc. (“MyoKardia”), the full extent of the impact of the coronavirus disease (“COVID-19”) pandemic on its operations and the development and commercialization of its products, potential laws and regulations to lower drug costs, market actions taken by private and government payers to manage drug utilization and contain costs, the expiration of patents or data protection on certain products, including assumptions about its ability to retain patent exclusivity of certain products and the impact and the result of governmental investigations. No forward-looking statement can be guaranteed, including that any future clinical studies will support the data described in documents incorporated by reference in the Offer to Purchase, product candidates will receive necessary clinical and manufacturing regulatory approvals, pipeline products will prove to be commercially successful, clinical and manufacturing regulatory approvals will be sought or obtained within currently expected timeframes or contractual milestones will be achieved. Such forward-looking statements are based on historical performance and current expectations and projections about Bristol Myers Squibb’s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond Bristol Myers Squibb’s control and could cause its future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to, risks relating to various risks related to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic on Bristol Myers Squibb’s operations and that it cannot reasonably assess or predict at this time the full extent of the adverse effect that the COVID-19 pandemic will have on its business, financial condition, results of operations and cash flows; increasing pricing pressures from market access, pharmaceutical pricing controls and discounting, changes to tax and importation laws and other restrictions in the United States, the European Union and other regions around the world that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; challenges inherent in new product development, including obtaining and maintaining regulatory approval; Bristol Myers Squibb’s ability to obtain and protect market exclusivity rights and enforce patents and other intellectual property rights; the possibility of difficulties and delays in product introduction and commercialization; the risk of certain novel approaches to disease treatment (such as CAR T therapy); industry competition from other manufacturers; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products, including without limitation, interruptions caused by damage to Bristol Myers Squibbs’ and its suppliers’ manufacturing sites; integrating Bristol Myers Squibb’s and Celgene’s business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting systems, sales operations and product distribution, pricing systems and methodologies, data security systems, compliance programs and internal controls processes; Bristol Myers Squibb’s ability to realize the anticipated benefits from the acquisition of Celgene; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; changes in tax law and regulations; the failure of Bristol Myers Squibb’s suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; Bristol Myers Squibb’s regulatory decisions impacting labeling, manufacturing processes and/or other matters; the impact on its competitive position from counterfeit or unregistered versions of its products or stolen products; the adverse impact of cyber-attacks on its information systems or products, including unauthorized disclosure of trade secrets or other confidential data stored in its information systems and networks; its ability to execute its financial, strategic and operational plans; Bristol Myers Squibb’s ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; Bristol Myers Squibb’s dependency on several key products; any decline in its future royalty streams; Bristol Myers Squibb’s ability to effectively manage acquisitions, divestitures, alliances and other portfolio actions and to successfully realize the expected benefits of such actions; Bristol Myers Squibb’s ability to attract and retain key personnel; the impact of its significant additional indebtedness that it incurred in connection with the acquisition of Celgene and the acquisition of MyoKardia and its issuance of additional shares in connection with the acquisition of Celgene on its ability to operate the combined company; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; the exclusive forum provision in its by-laws for certain lawsuits could limit its stockholders’ ability to obtain a judicial forum that it finds favorable for such lawsuits; and issuance of new or revised accounting standards. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2020, as updated by its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. corporatefinancial—news View source version on businesswire.com:https://www.businesswire.com/news/home/20210219005504/en/ CONTACT: Bristol Myers Squibb Media: [email protected] Investor Relations: Tim Power 609-252-7509 [email protected] Nina Goworek 908-673-9711 [email protected] KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: BIOTECHNOLOGY FDA HEALTH PHARMACEUTICAL CLINICAL TRIALS SOURCE: Bristol Myers Squibb Copyright Business Wire 2021. PUB: 02/19/2021 05:04 PM/DISC: 02/19/2021 05:04 PM http://www.businesswire.com/news/home/20210219005504/en ApproximateProrationFactor Celgene WhatsApp $231,758,000 5.000% Notes due 2045* 2 36.23% CUSIP/ISINNumber(s) Bristol Myers Squibb 0.436% $120,468,000 TotalConsideration (2) $636,086,000 CUSIP/ISINNumber(s) Celgene $33,453,000 3.031% $40,476,000 2.900% Notes due 2024 $23,523,000 Twitter $231,758,000 $1,089.89 3 $1,369.75 151020AJ3 2.971% 1 $1,412.08 $557,311,000 2024 Pool Offers to purchase for cash up to $1,500,000,000 aggregate purchase price for the securities listed in the priority order below. 100% 0.351% 0.353% 100% Title of Security $1,096.90 2025 Pool Offers to purchase for cash up to $650,000,000 aggregate purchase price for the securities listed in the priority order below. 4.000% Notes due 2023 Title of Security 110122DC9/ 110122BN7/ U11009AN4 151020AS3 100% 2 100% 5.700% Notes due 2040 3.031% $1,368.80 100% CUSIP/ISINNumber(s) $2,379,532,000 Bristol Myers Squibb Principal AmountAccepted PrincipalAmountTendered as of theEarly TenderDeadline Bristol Myers Squibb 3.625% Notes due 2024* 151020AP9 100% $937,341,000 $22,619,000 $22,619,000 $1,089.89 6.125% Notes due 2038 Principal AmountAccepted $1,130.97 $3,750,000,000 $56,905,000 Bristol Myers Squibb TAGS High Coupon Pool Offers to purchase for cash up to $900,000,000 aggregate purchase price for the securities listed in the priority order below. TotalConsideration (2) 6 100% $7,004,000 151020AM6 Issuer / Offeror $62,818,000 $3,250,000,000 2.981% PrincipalAmountOutstanding – $1,083.67 1 PrincipalAmountOutstanding Celgene $2,185,000 $772,109,000 $582,075,000 7.150% Notes due 2023 3.031% $1,054,294,000 $1,959,524,000 0.724% 5.000% Notes due 2045* 24.15% $245,785,000 $1,346.20 Pinterest – Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion 100% $1,096.90 2.931% 52.90% Facebook $2,132,607,000 Issuer / Offeror PrincipalAmountTendered as of theEarly TenderDeadline 5.700% Notes due 2040 Includes the Early Tender Premium (as defined in the Offer to Purchase). Payable per each $1,000 principal amount of each specified series of Notes validly tendered at or prior to the Early Tender Deadline and accepted for purchase. AcceptancePriorityLevel $117,490,000 $1,392.87 The “Offer Yield” is equal to the applicable Reference Yield (as defined in the Offer to Purchase), which is based on the bid-side price of the applicable Reference U.S. Treasury Security (as specified in the Offer to Purchase)) plus the applicable Fixed Spread (as specified in the Offer to Purchase). 3.625% Notes due 2024* 110122CM8/ 110122BZ0/ U11009AZ7 Celgene Previous articleTorino wins 1-0 at Cagliari to boost hopes of staying upNext articleNFL’s Kamara races into NASCAR as a team sponsor at Daytona Digital AIM Web Support 110122DJ4/ 110122BU1/ U11009AU8 110122AC2 $226,259,000 2.971% Bristol Myers Squibb Bristol Myers Squibb 1 ApproximateProrationFactor 2 5.875% Notes due 2036 0.724% Bristol Myers Squibb $19,832,000 $7,453,000 $4,215,000 3.781% $23,765,000 $1,169,000 2.981% 0.351% 6.875% Notes due 2097 110122DA3/ 110122BL1/ U11009AL8 $86,896,000 110122DG0/ 110122BS6/ U11009AS3 Celgene $7,004,000 110122AQ1 $1,771.55 $286,673,000 4.625% Notes due 2044* WhatsApp 5.250% Notes due 2043 $7,453,000 $56,905,000 – 0.353% $117,622,000 ApproximateProrationFactor $366,000 3.875% Notes due 2025* $63,914,000 $1,392.87 Issuer / Offeror 3.875% Notes due 2025* Issuer / Offeror 1 $19,832,000 Facebook 110122DH8/ 110122BT4/ U11009AT1 $5,727,000 $1,130.97 151020AU8 Principal AmountAccepted $117,622,000 100% TotalConsideration (2) 1 100% $8,075,000 $391,925,000 151020AL8 By Digital AIM Web Support – February 19, 2021 2.931% Offer Yield (1) $226,063,000 Pinterest 4.625% Notes due 2044* $1,369.75 8 ApproximateProrationFactor 4.250% Notes due 2049* $14,081,000 $1,279.59 Principal AmountAccepted Celgene PrincipalAmountOutstanding 100% Bristol Myers Squibb (1) Bristol Myers Squibb $1,346.20 100% $1,169,000 AcceptancePriorityLevel 100% 5 $366,000 $1,279.59 110122DB1/ 110122BM9/ U11009AM6 $976,477,000 1 Bristol Myers Squibb $582,075,000 AcceptancePriorityLevel $2,185,000 PrincipalAmountTendered as of theEarly TenderDeadline 151020AF1 Offer Yield (1) 7 52.90% Offer Yield (1) TotalConsideration (2) $14,081,000 5.250% Notes due 2043 $62,818,000 4 110122AA6 2 5 Bristol Myers Squibb 110122CR7/ 110122CD8/ U11009BD5 Bristol Myers Squibb (2) $882,510,000 $256,371,000 $256,371,000 $1,127,899,000 Celgene 7 CUSIP/ISINNumber(s) Title of Security $301,532,000 AcceptancePriorityLevel 0.259% 100% Twitter – 110122DF2/ 110122BR8/ U11009AR5 2.931%
Pinterest Important message for people attending LUH’s INR clinic By News Highland – November 29, 2017 There have been a number of reports relating to the possible use of ‘key lock jammers’ in Letterkenny, Bridgend, Lifford and Strabane areas.These devices send a remote signal that stops owners locking / opening car doors.In turn this may appear to indicate a faulty car key battery, when in fact the signal to lock the car door has been stopped leaving your vehicle open.Police are asking to people to check the door handle prior to leaving your vehicle unattended.Malcholm Boyd, Specialist in car keys with North West locks says they have been inunadated this week:Audio Playerhttp://www.highlandradio.com/wp-content/uploads/2017/11/keyjammefgffrs1pm.mp300:0000:0000:00Use Up/Down Arrow keys to increase or decrease volume. DL Debate – 24/05/21 WhatsApp Twitter News, Sport and Obituaries on Monday May 24th Loganair’s new Derry – Liverpool air service takes off from CODA Arranmore progress and potential flagged as population grows Facebook RELATED ARTICLESMORE FROM AUTHOR Pinterest Google+ Facebook WhatsApp Twitter Warning over use of ‘key lock jammers’ in Donegal & Tyrone Google+ Homepage BannerNews Previous articleCar parking charges in Donegal to be reviewed in New YearNext articleInsurance company reject compensation claims by Mica homeowners News Highland Nine til Noon Show – Listen back to Monday’s Programme
We firmly establish a certain class of post-midnight ELF/VLF wave events as a signature of the substorm expansion phase. These substorm chorus events (SCEs) have been observed near L = 4 at Halley, Antarctica (76°S, 27°W), by the VELOX instrument. By examining 4 years (1992–1995) of nearly continuous Halley VELOX data, we identified 973 SCEs. From this database a subset of 258 events was selected, occurring within ±1 hour of local magnetic midnight at Halley, that is, between 0200 and 0400 UT. The epochs of these events were used to perform a superposed epoch analysis on the three components of the Halley fluxgate magnetometer data. A significant negative bay in the magnetic H component was observed to start at the SCE epoch, as expected for a ground station near the westward electrojet of the substorm current wedge. Positive and negative bays, respectively, were seen in the D and Z components. We interpret the detailed features of the composite magnetograms and conclude that the SCE is an unambiguous signature of substorm expansion phase onset. Given this association of the SCE with the substorm expansion phase based on the qualitative features of the superposed epoch ground magnetic signature, this paper also provides the most complete quantitative description to date of both the VLF and magnetic substorm signatures observed at a near-auroral zone ground station.
The quality of Oxford’s quads and lawns could be severely affected this term as college gardeners are faced with a hosepipe ban.The ban was brought in on 5th April in order to combat the drought currently plaguing much of England, which over the past few days has spread beyond the Southeast of the country to affect as many as twenty million people. The Environment Agency has warned that restrictions may last until Christmas.An investigation carried out by Cherwell last year revealed that 50% of the eighteen colleges questioned employ sprinkler systems to water their lawns. Of these, several obtain water through natural means, such as by collecting rainwater, or, as in the case of Worcester, by redistributing water from the lake over the quads.A number of these colleges, including Jesus and St John’s, specified that their sprinkler systems were not “plumbed in”, but were rather used only when required. Nevertheless, all such colleges will be forced to find other ways to water their quads as the dry summer approaches.The University Parks Department maintains the gardens of a number of colleges, including Exeter, Oriel and Brasenose. Walter Sawyer, the superintendent of the University Parks, said that the ban would be strictly adhered to. “There simply won’t be any watering with hose pipes and sprinklers on any of the established sites that we manage. The drought order is very clear [in that] it does not permit watering in established gardens using these techniques”.When asked how he intended to keep the lawns looking pristine, he pointed to the legality of methods such as the watering can, bowser, or water tank. He also acknowledged the Parks’ fortunate position, in that “few colleges have any water collection facilities. We have some large underground rainwater collecting water tanks in the Parks that will supply some of [the] needs here”.Bruce Taylor, the head gardener at University College, commented, “Obviously for the foreseeable future we will not be using [the sprinkler system], and so the lawns will not be watered.”However, he remained optimistic as to the state of the lawns. Whilst conceding that “a green lawn looks far superior to a brown one”, he stated that “grass is the most resilient of plants and lengthy droughts are unlikely to kill it. If we do have moist conditions over the summer then there are chemicals that we can apply just to green it up a bit”.Despite the efforts clearly being made to maintain lawns, certain students at University College remain unimpressed. A first year student said that he was “disgusted” at the prospect of brown lawns, and concerns were also raised as to the effects of discoloured lawns upon potential applicants at the July open days. A New College cricketer questioned the impact that the ban may have on sports fields. He argued, “The Parks wouldn’t be the same without its lush, green outfield; anything less just isn’t cricket.”Jules Ginsberg, an undergraduate at St Catherine’s College, was more conciliatory. She commented, “It’s unfortunate that during croquet season the lawns will be less green,” yet conceded, “I do think that a hosepipe ban is necessary in light of the drought. However, if ever there was a time to let it rain on our parade, that time would be now.”
Northern Irish baker Irwin’s has been awarded funding from the Irish Central Border Area Network (ICBAN) to develop its range of “smart breads”.Irwin’s intends to use the new £28,000 grant to develop breads aimed at tackling a range of health issues in Northern Ireland. MD Brian Irwin said the baker has already achieved a number of UK and Ireland industry firsts with functional breads – including folic acid fortified breads, added-calcium children’s products, reduced salt breads and, most recently, a low-Glycaemic Index white loaf, with a GI ranking of 39.“With the help of the ICBAN award, we are now aiming to take our capabilities in this area even further – by creating more breads capable of addressing other specific health concerns prevalent here, such as heart disease, in a much more targeted and impactful way,” said Mr Irwin.The ICBAN bursary was made possible through Euro-pean Union funding.